SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 14, 2002; DOI 10.1182/blood-2002-01-0230. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0230v1 100/7/2349    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Maynadié, M. Articles by Feuillard, J. Search for Related Content PubMed PubMed Citation Articles by Maynadié, M. Articles by Feuillard, J. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 October 2002, Vol. 100, No. 7, pp. 2349-2356 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Immunophenotypic clustering of myelodysplastic syndromes Marc Maynadié, Françoise Picard, Bernard Husson, Bernard Chatelain, Yvan Cornet, Geneviève Le Roux, Lydia Campos, Alex Dromelet, Pascalle Lepelley, Hélène Jouault, Michèle Imbert, Michelle Rosenwadj, Véronique Vergé, Philippe Bissières, Martine Raphaël, Marie Christine Béné, Jean Feuillard, and the Groupe d'Etude Immunologique des Leucémies (GEIL) From the Service d'Hématologie Biologique, CHU Bocage, Dijon, France; Service d'Hématologie Biologique Hôpital Cochin AP-HP and Laboratoire d'Immuno-Hématologie, Hôpital Saint-Antoine, Paris, France; Laboratoire de Biologie Clinique, Hôpital de Jolimont, Haine Saint Paul, Belgium; Laboratoire d'Hématologie, Cliniques Universitaires UCL Mont Godinne, Yvoir, Belgium; Laboratoire d'Hématologie, Hôpital Nord, CHU Saint Etienne, France; Laboratoire d'Hématologie A, Hôpital Calmette, CHU Lille, France; Laboratoire d'Hématologie, Hôpital Henri Mondor AP-HP, Créteil, France; Laboratoire d'Immunologie, Faculté de Médecine, Vandoeuvre-Les-Nancy, France; and Service d'Hématologie Biologique, Hôpital Avicenne AP-HP et EA 3406 ATHSCO, Université Paris 13, Bobigny, France. GEIL: Groupe d'Etude Immunologique des Leucémies. Myelodysplastic syndromes (MDSs) are heterogeneous diseases of bone marrow (BM) cell precursors for which immunophenotypic characterization is still considered irrelevant despite the accuracy and sensitivity of flow cytometry techniques. The aim of this study was to determine whether immunophenotypic abnormalities could be defined in MDSs and could correlate with the French-American-British classification and cytogenetics. Analysis was performed on 275 BM samples (207 MDS patients, 68 controls) and 25 control blood samples. Immunophenotyping was based on a primary gating of blast cells, monocytes, and granulocytes according to CD45 antigen expression and side scatter light diffraction. Immunophenotypic hierarchical clustering was performed to analyze the results. The data obtained show that (1) immunophenotypic clustering partly discriminates patients with refractory anemia with excess blasts/refractory anemia with excess blasts in transformation (RAEB/RAEB-T), chronic myelomonocytic leukemia (CMML), and refractory anemia/refractory anemia with ring sideroblasts (RA/RARS) for CD45lo blast cells and patients with RA/CMML, RARS, and RAEB/RAEB-T for CD45hi/side scatterhi (SShi) granulocytes; (2) the most discriminating markers were CD16, CD34, CD36, CD38, CD71, and HLA-DR for blast cells and CD11b, CD13, CD33, CD36, CD38, CD71, and HLA-DR for CD45hi/SShi granulocytes; (3) clusters related to CD34 expression were associated with high levels of blast cells on BM smear; (4) clusters related to high levels of CD36 expression on CD45lo blast cells and CD45hi/SShi granulocytes were associated with a poor International Prognosis Scoring System score; and (5) high levels of CD71 expression on CD45hi/SShi granulocytes were associated with the RARS category. These results show a close relationship between immunophenotypic abnormalities and BM dysplasia and suggest that flow cytometry could be a future tool for the characterization of MDSs. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. E. Craig and K. A. Foon Flow cytometric immunophenotyping for hematologic neoplasms Blood, April 15, 2008; 111(8): 3941 - 3967. [Abstract] [Full Text] [PDF] A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry Blood, February 1, 2008; 111(3): 1067 - 1077. [Abstract] [Full Text] [PDF] D. A. Wells, M. Benesch, M. R. Loken, C. Vallejo, D. Myerson, W. M. Leisenring, and H. J. Deeg Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation Blood, July 1, 2003; 102(1): 394 - 403. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020